| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 03/11/2023 | 22:31 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 07/08/2023 | 22:15 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 21/06/2023 | 23:25 | Edgar (US Regulatory) | Post-effective Amendment to Registration Statement (pos Am) | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 20/06/2023 | 23:02 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 05/06/2023 | 15:00 | GlobeNewswire Inc. | Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the A | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 15/05/2023 | 21:18 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 09/05/2023 | 12:03 | Edgar (US Regulatory) | Notification That Quarterly Report Will Be Submitted Late (nt 10-q) | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 12/04/2023 | 14:51 | Edgar (US Regulatory) | Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse) | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 10/04/2023 | 23:23 | Edgar (US Regulatory) | Amended Current Report Filing (8-k/a) | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 21/03/2023 | 00:54 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 10/03/2023 | 17:22 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 22/02/2023 | 15:25 | AllPennyStocks.com | Bankruptcy Court Approval Causes Premarket Buying Pressure | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 21/02/2023 | 23:57 | PR Newswire (US) | Sorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 Case | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 20/02/2023 | 17:00 | GlobeNewswire Inc. | Sorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”) | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 20/02/2023 | 17:00 | GlobeNewswire Inc. | Sorrento Issues Update to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”) | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 16/02/2023 | 20:41 | PR Newswire (US) | Sorrento Therapeutics, Inc. Receives Court Approval for "First Day" Employee Wages and Cash Management Motions | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 13/02/2023 | 21:46 | GlobeNewswire Inc. | Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today’s Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc. | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 13/02/2023 | 00:48 | GlobeNewswire Inc. | Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB™ in the U.S. and Canada for the acute treatment of migraine | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 05/02/2023 | 04:48 | GlobeNewswire Inc. | Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of Stockholders | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 04/02/2023 | 02:59 | GlobeNewswire Inc. | Sorrento Distributes Dividend Confirmation Statements to 146 Brokerage Firms and Provides Specific Instruction to Continental Stock Transfer & Trust Company Regarding the Dividend of Scilex Holding Company Common Stock | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 02/02/2023 | 19:15 | GlobeNewswire Inc. | Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 30/01/2023 | 04:26 | GlobeNewswire Inc. | Sorrento Issues “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 30/01/2023 | 03:55 | GlobeNewswire Inc. | Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued an “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 09/01/2023 | 15:00 | GlobeNewswire Inc. | Sorrento Releases Positive Results from a Phase 1b Study in China in COVID-19 Patients and is Ready for Pivotal Phase 3 trials with OVYDSO™ (STI-1558), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 19/12/2022 | 12:03 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 06/12/2022 | 15:00 | GlobeNewswire Inc. | Sorrento Therapeutics has Received FDA Clearance to Initiate Clinical Trials with a Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 05/12/2022 | 21:01 | GlobeNewswire Inc. | Sorrento Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology (ESMO) | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 29/11/2022 | 20:06 | GlobeNewswire Inc. | Sorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from a Phase Ib Study in China with STI-1558, an Oral M(pro) Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Bo | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 13/11/2022 | 21:02 | GlobeNewswire Inc. | Sorrento to Host Webcast to Discuss Newly Presented Clinical Data Demonstrating Significant Improvements in Therapeutic Outcomes in 10 of 10 Patients with Poorly Controlled Rheumatoid Arthritis | NASDAQ:SRNE | Sorrento Therapeutics Inc |
| 10/11/2022 | 20:45 | GlobeNewswire Inc. | Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), Debuts on Nasdaq Under Ticker “SCLX” | NASDAQ:SRNE | Sorrento Therapeutics Inc |